Welcome to our dedicated page for RVPHW SEC filings (Ticker: RVPHW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reviva Pharmaceuticals Holdings, Inc. filings document material-event disclosures for a public pharmaceutical operating company, including 8-K reports on operating and financial results, Regulation FD updates, material agreements, clinical or regulatory matters, capital-structure disclosures, and Nasdaq continued-listing compliance.
The records also cover security-holder rights, certificate or bylaw amendments, registered common stock information, security-structure disclosures, exhibits, press releases, and Inline XBRL cover-page data.
REVIVA PHARMACEUTICALS HOLDINGS, INC. Chief Financial Officer Prabhu Narayan received a grant of stock options covering 40,925 shares of common stock on the grant date of March 18, 2026. These options have an exercise price of $1.87 per share and expire on March 17, 2036.
The award vests over time under the company’s 2020 Equity Incentive Plan. Of the total, 12,789 option shares vested immediately on the grant date, while the remaining 28,136 shares will vest in equal monthly installments from April 2026 through December 2028, encouraging long-term alignment with the company.
REVIVA PHARMACEUTICALS HOLDINGS, INC. Chief Financial Officer Prabhu Narayan received a grant of stock options covering 40,925 shares of common stock on the grant date of March 18, 2026. These options have an exercise price of $1.87 per share and expire on March 17, 2036.
The award vests over time under the company’s 2020 Equity Incentive Plan. Of the total, 12,789 option shares vested immediately on the grant date, while the remaining 28,136 shares will vest in equal monthly installments from April 2026 through December 2028, encouraging long-term alignment with the company.
REVIVA PHARMACEUTICALS HOLDINGS, INC. President and CEO Laxminarayan Bhat reported receiving two stock option awards under the company’s 2020 Equity Incentive Plan. The grants cover a total of 150,075 options to buy common stock at an exercise price of $1.87 per share, expiring on March 17, 2036.
One option for 109,150 shares is held directly and another for 40,925 shares is held indirectly through his spouse. For the direct grant, 34,110 options vest immediately and 75,040 vest in equal monthly installments from April 2026 to December 2028. For the spouse-held grant, 12,789 options vest immediately and 28,136 vest on the same monthly schedule. These are compensation-related awards, not open‑market share purchases or sales.
REVIVA PHARMACEUTICALS HOLDINGS, INC. President and CEO Laxminarayan Bhat reported receiving two stock option awards under the company’s 2020 Equity Incentive Plan. The grants cover a total of 150,075 options to buy common stock at an exercise price of $1.87 per share, expiring on March 17, 2036.
One option for 109,150 shares is held directly and another for 40,925 shares is held indirectly through his spouse. For the direct grant, 34,110 options vest immediately and 75,040 vest in equal monthly installments from April 2026 to December 2028. For the spouse-held grant, 12,789 options vest immediately and 28,136 vest on the same monthly schedule. These are compensation-related awards, not open‑market share purchases or sales.
Reviva Pharmaceuticals Holdings, Inc. has entered into agreements for a registered public offering raising aggregate gross proceeds of $10.0 million. The company will sell 6,283,334 shares of common stock and pre-funded warrants for up to 383,333 shares, together with Series G and Series H warrants exercisable for up to 6,666,667 shares each at an exercise price of $1.50 per share. Net proceeds are expected to be approximately $9.0 million, which Reviva plans to use, along with existing cash, to fund research and development, including its planned RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia, and for working capital and general corporate purposes. The warrants are immediately exercisable, with Series G expiring in five years and Series H in one year, and include beneficial ownership limits of 4.99% or 9.99%.
Reviva Pharmaceuticals Holdings, Inc. has entered into agreements for a registered public offering raising aggregate gross proceeds of $10.0 million. The company will sell 6,283,334 shares of common stock and pre-funded warrants for up to 383,333 shares, together with Series G and Series H warrants exercisable for up to 6,666,667 shares each at an exercise price of $1.50 per share. Net proceeds are expected to be approximately $9.0 million, which Reviva plans to use, along with existing cash, to fund research and development, including its planned RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia, and for working capital and general corporate purposes. The warrants are immediately exercisable, with Series G expiring in five years and Series H in one year, and include beneficial ownership limits of 4.99% or 9.99%.
Reviva Pharmaceuticals Holdings, Inc. is offering 6,283,334 shares of common stock together with Series G and Series H common warrants and up to 383,333 Pre-Funded Warrants in a primary, best-efforts offering described in this prospectus supplement.
The combined public offering price is $1.50 per share and accompanying Series G and H Common Warrants; Series G warrants expire five years and Series H warrants expire 12 months after issuance. Pre-Funded Warrants carry a $0.0001 exercise price and may be used to avoid exceeding 4.99% (or, at purchaser election, 9.99%) beneficial ownership limits. The offering may terminate on April 13, 2026 and is expected to settle in a single closing; proceeds to the issuer are described as net of Placement Agent fees.
The prospectus supplement gives effect to a one-for-twenty reverse stock split effective March 9, 2026. Shares outstanding used to calculate post-offering figures are 6,443,710 as of March 17, 2026.
Reviva Pharmaceuticals Holdings, Inc. is offering 6,283,334 shares of common stock together with Series G and Series H common warrants and up to 383,333 Pre-Funded Warrants in a primary, best-efforts offering described in this prospectus supplement.
The combined public offering price is $1.50 per share and accompanying Series G and H Common Warrants; Series G warrants expire five years and Series H warrants expire 12 months after issuance. Pre-Funded Warrants carry a $0.0001 exercise price and may be used to avoid exceeding 4.99% (or, at purchaser election, 9.99%) beneficial ownership limits. The offering may terminate on April 13, 2026 and is expected to settle in a single closing; proceeds to the issuer are described as net of Placement Agent fees.
The prospectus supplement gives effect to a one-for-twenty reverse stock split effective March 9, 2026. Shares outstanding used to calculate post-offering figures are 6,443,710 as of March 17, 2026.
Reviva Pharmaceuticals Holdings approved a one-for-twenty reverse stock split of its common stock, effective at 12:01 a.m. Eastern Time on March 9, 2026. Every 20 existing shares will convert into 1 share, with no fractional shares issued; holdings will be rounded up to the next whole share.
The par value and authorized share count will not change, but outstanding options and warrants will be adjusted for the new ratio. Reviva is using the reverse split as a key step to regain compliance with Nasdaq’s $1.00 minimum bid price requirement after receiving a delisting notice and a compliance extension through March 27, 2026.
The company warns that the reverse split announcement and implementation could pressure the stock price, reduce trading liquidity due to fewer outstanding shares, and that failure to meet Nasdaq’s listing standards could lead to delisting, harming liquidity, market value, and capital-raising ability.
Reviva Pharmaceuticals Holdings approved a one-for-twenty reverse stock split of its common stock, effective at 12:01 a.m. Eastern Time on March 9, 2026. Every 20 existing shares will convert into 1 share, with no fractional shares issued; holdings will be rounded up to the next whole share.
The par value and authorized share count will not change, but outstanding options and warrants will be adjusted for the new ratio. Reviva is using the reverse split as a key step to regain compliance with Nasdaq’s $1.00 minimum bid price requirement after receiving a delisting notice and a compliance extension through March 27, 2026.
The company warns that the reverse split announcement and implementation could pressure the stock price, reduce trading liquidity due to fewer outstanding shares, and that failure to meet Nasdaq’s listing standards could lead to delisting, harming liquidity, market value, and capital-raising ability.
683 Capital Management, 683 Capital Partners and Ari Zweiman filed Amendment No. 1 to a Schedule 13G updating their ownership in Reviva Pharmaceuticals Holdings, Inc. They may be deemed to beneficially own warrants to purchase 3,492,500 shares of common stock, all currently exercisable.
Based on 115,058,619 shares of common stock outstanding as of November 11, 2025, plus these warrant shares, their holdings represent about 3.0% of Reviva’s common stock. The filers state this amendment is an exit filing because they no longer own more than five percent and certify the securities are not held to change or influence control of the company.
683 Capital Management, 683 Capital Partners and Ari Zweiman filed Amendment No. 1 to a Schedule 13G updating their ownership in Reviva Pharmaceuticals Holdings, Inc. They may be deemed to beneficially own warrants to purchase 3,492,500 shares of common stock, all currently exercisable.
Based on 115,058,619 shares of common stock outstanding as of November 11, 2025, plus these warrant shares, their holdings represent about 3.0% of Reviva’s common stock. The filers state this amendment is an exit filing because they no longer own more than five percent and certify the securities are not held to change or influence control of the company.
Reviva Pharmaceuticals Holdings, Inc. reports that a Nasdaq Hearings Panel has granted the company an exception to regain compliance with Nasdaq’s $1.00 minimum bid price requirement for continued listing through March 27, 2026. This gives the company more time to bring its share price back above the required level.
The company adds a new risk factor explaining that it may implement a reverse stock split to help meet the bid price rule and that such a split could negatively affect its share price and trading liquidity. Reviva warns that failure to regain or maintain compliance with Nasdaq listing standards could lead to delisting, which could hurt the stock’s liquidity, price, and the company’s ability to raise capital or pursue business opportunities.
Reviva Pharmaceuticals Holdings, Inc. reports that a Nasdaq Hearings Panel has granted the company an exception to regain compliance with Nasdaq’s $1.00 minimum bid price requirement for continued listing through March 27, 2026. This gives the company more time to bring its share price back above the required level.
The company adds a new risk factor explaining that it may implement a reverse stock split to help meet the bid price rule and that such a split could negatively affect its share price and trading liquidity. Reviva warns that failure to regain or maintain compliance with Nasdaq listing standards could lead to delisting, which could hurt the stock’s liquidity, price, and the company’s ability to raise capital or pursue business opportunities.
Dr. Laxminarayan Bhat amended his Schedule 13D to report beneficial ownership of 3,680,874 shares of Reviva Pharmaceuticals Holdings, Inc. common stock, representing approximately 3.8% of the outstanding shares based on 96,337,119 shares outstanding as of September 22, 2025. Of those shares, Dr. Bhat has sole voting and dispositive power over 3,352,177 shares, which includes 2,478,856 shares held outright and 873,321 options exercisable within 60 days. An additional 328,697 shares are shared with his spouse, primarily through options exercisable within 60 days. The filing notes Dr. Bhat ceased to be a beneficial owner of more than 5% as of September 22, 2025 and reported no transactions in the prior 60 days.
Dr. Laxminarayan Bhat amended his Schedule 13D to report beneficial ownership of 3,680,874 shares of Reviva Pharmaceuticals Holdings, Inc. common stock, representing approximately 3.8% of the outstanding shares based on 96,337,119 shares outstanding as of September 22, 2025. Of those shares, Dr. Bhat has sole voting and dispositive power over 3,352,177 shares, which includes 2,478,856 shares held outright and 873,321 options exercisable within 60 days. An additional 328,697 shares are shared with his spouse, primarily through options exercisable within 60 days. The filing notes Dr. Bhat ceased to be a beneficial owner of more than 5% as of September 22, 2025 and reported no transactions in the prior 60 days.
Dr. Laxminarayan Bhat amended his Schedule 13D to report beneficial ownership of 3,680,874 shares of Reviva Pharmaceuticals Holdings, Inc. common stock, representing approximately 3.8% of the outstanding shares based on 96,337,119 shares outstanding as of September 22, 2025. Of those shares, Dr. Bhat has sole voting and dispositive power over 3,352,177 shares, which includes 2,478,856 shares held outright and 873,321 options exercisable within 60 days. An additional 328,697 shares are shared with his spouse, primarily through options exercisable within 60 days. The filing notes Dr. Bhat ceased to be a beneficial owner of more than 5% as of September 22, 2025 and reported no transactions in the prior 60 days.
Dr. Laxminarayan Bhat amended his Schedule 13D to report beneficial ownership of 3,680,874 shares of Reviva Pharmaceuticals Holdings, Inc. common stock, representing approximately 3.8% of the outstanding shares based on 96,337,119 shares outstanding as of September 22, 2025. Of those shares, Dr. Bhat has sole voting and dispositive power over 3,352,177 shares, which includes 2,478,856 shares held outright and 873,321 options exercisable within 60 days. An additional 328,697 shares are shared with his spouse, primarily through options exercisable within 60 days. The filing notes Dr. Bhat ceased to be a beneficial owner of more than 5% as of September 22, 2025 and reported no transactions in the prior 60 days.
Amendment No. 11 to the Schedule 13D updates beneficial ownership disclosures for Parag Saxena and Vedanta Partners, LLC in Reviva Pharmaceuticals Holdings, Inc. (ticker RVPH). As of the filing date, Vedanta Partners reports beneficial ownership of 5,367,069 shares, representing 5.4% of the 96,337,119 shares outstanding. Mr. Saxena is deemed to beneficially own 6,259,806 shares, or 6.2%, including directly held shares, shares held through related partnerships, vested options and securities underlying warrants and pre-funded warrants. The filing states no transactions occurred in the prior 60 days and explains certain exercise limitations on warrants that prevent ownership above 4.99% for some holders.
Amendment No. 11 to the Schedule 13D updates beneficial ownership disclosures for Parag Saxena and Vedanta Partners, LLC in Reviva Pharmaceuticals Holdings, Inc. (ticker RVPH). As of the filing date, Vedanta Partners reports beneficial ownership of 5,367,069 shares, representing 5.4% of the 96,337,119 shares outstanding. Mr. Saxena is deemed to beneficially own 6,259,806 shares, or 6.2%, including directly held shares, shares held through related partnerships, vested options and securities underlying warrants and pre-funded warrants. The filing states no transactions occurred in the prior 60 days and explains certain exercise limitations on warrants that prevent ownership above 4.99% for some holders.
Amendment No. 11 to the Schedule 13D updates beneficial ownership disclosures for Parag Saxena and Vedanta Partners, LLC in Reviva Pharmaceuticals Holdings, Inc. (ticker RVPH). As of the filing date, Vedanta Partners reports beneficial ownership of 5,367,069 shares, representing 5.4% of the 96,337,119 shares outstanding. Mr. Saxena is deemed to beneficially own 6,259,806 shares, or 6.2%, including directly held shares, shares held through related partnerships, vested options and securities underlying warrants and pre-funded warrants. The filing states no transactions occurred in the prior 60 days and explains certain exercise limitations on warrants that prevent ownership above 4.99% for some holders.
Amendment No. 11 to the Schedule 13D updates beneficial ownership disclosures for Parag Saxena and Vedanta Partners, LLC in Reviva Pharmaceuticals Holdings, Inc. (ticker RVPH). As of the filing date, Vedanta Partners reports beneficial ownership of 5,367,069 shares, representing 5.4% of the 96,337,119 shares outstanding. Mr. Saxena is deemed to beneficially own 6,259,806 shares, or 6.2%, including directly held shares, shares held through related partnerships, vested options and securities underlying warrants and pre-funded warrants. The filing states no transactions occurred in the prior 60 days and explains certain exercise limitations on warrants that prevent ownership above 4.99% for some holders.
Reviva Pharmaceuticals Holdings, Inc. filed a Current Report disclosing that on September 18, 2025 it launched and priced an offering of securities and entered into a Placement Agency Agreement with A.G.P./Alliance Global Partners to market the offering. The company agreed to pay the placement agent a cash fee equal to 7.0% of aggregate gross proceeds (with a 3.5% fee for proceeds from certain investors as mutually agreed) and to reimburse up to $15,000 for non-accountable expenses and up to $75,000 for out-of-pocket accountable legal expenses. The filing references executed forms of Series E and Series F warrants, a securities purchase agreement, the placement agency agreement, legal opinion of Lowenstein Sandler LLP, and press releases announcing the launch and pricing of the offering as exhibits.
The report includes a forward-looking statement caution noting risks to closing the offering and to anticipated proceeds; the filing does not state the final offering size or the exact proceeds expected in this Current Report text.